BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)
Supplemental material
Ann Rheum Dis
Supplementary Figure 1 . Days to symptom resolution in those with breakthrough versus non- breakthrough COVID-19 infection over 204-day follow-up period (Unadjusted Analysis)
A. Cumulative incidence curves for time to symptom resolution, comparing breakthrough versus non- breakthrough infection. B and C, mean post-symptom resolution time spans as the area under the cumulative incidence curves in those with breakthrough versus non-breakthrough infection, respectively, across 204 days of follow-up.
Supplementary Figure 2A . Days to symptom resolution in those with breakthrough versus non- breakthrough COVID-19 infection over 28-day follow-up period (Unadjusted Analysis)
A. Cumulative incidence curves for time to symptom resolution, comparing breakthrough versus non- breakthrough infection. B and C, mean post-symptom resolution time spans as the area under the cumulative incidence curves in those with breakthrough versus non-breakthrough infection, respectively, across 28 days of follow-up.
Supplementary Figure 2B . Days to symptom resolution in those with breakthrough versus non- breakthrough COVID-19 infection over 28-day follow-up period (Adjusted Analysis)
A. Cumulative incidence curves for time to symptom resolution, comparing breakthrough versus non- breakthrough infection. B and C, mean post-symptom resolution time spans as the area under the cumulative incidence curves in those with breakthrough versus non-breakthrough infection, respectively, across 28 days of follow-up.
Supplementary Figure 3A . Days to symptom resolution in those with breakthrough versus non- breakthrough COVID-19 infection over 90-day follow-up period (Unadjusted Analysis)
A. Cumulative incidence curves for time to symptom resolution, comparing breakthrough versus non- breakthrough infection. B and C, mean post-symptom resolution time spans as the area under the cumulative incidence curves in those with breakthrough versus non-breakthrough infection, respectively, across 90 days of follow-up.
Supplementary Figure 3B . Days to symptom resolution in those with breakthrough versus non- breakthrough COVID-19 infection over 90-day follow-up period (Adjusted Analysis)
A. Cumulative incidence curves for time to symptom resolution, comparing breakthrough versus non- breakthrough infection. B and C, mean post-symptom resolution time spans as the area under the cumulative incidence curves in those with breakthrough versus non-breakthrough infection, respectively, across 90 days of follow-up.
2022;0:1–9. doi: 10.1136/ard-2022-223439 Ann Rheum Dis , et al. Patel NJ
Powered by FlippingBook